AAIC

Cost-effectiveness of amyloid-targeting therapies: modelling based on 5724 biomarker positive AD patients in the Swedish Registry of Cognitive Disorders

References

1. L Jönsson, A Wimo. Viewpoint: Amyloid-targeting New Therapies for Alzheimer’s Disease: A Health Economics Perspective. J Prev Alzheimers Dis 2023;10(2):349-352. doi: 10.14283/jpad.2023.76.
2. F Landeiro, J Morton, A Gustavsson et al. Health economic modeling for Alzheimer’s disease: Expert perspectives. Alzheimers Dement (N Y) 2022 Oct 26;8(1):e12360. doi: 10.1002/trc2.12360.
3. A Gustavsson, L Raket, M Lilja et al. Health utility in preclinical and prodromal Alzheimer’s disease for establishing the value of new disease-modifying treatments-EQ-5D data from the Swedish BioFINDER study. Alzheimers Dement. 2021 Nov;17(11):1832-1842. doi: 10.1002/alz.12355
4. L Jönsson, N Andreassen, L Kilander et al. Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL. Alzheimer Dis Assoc Disord. 2006 Jan-Mar;20(1):49-55.
5. C van Dyck, C Swanson, P Aisen et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948.

Contact details

Linus Jönsson
Karolinska Institutet
linus.jonsson@ki.se
Phone: +46708673522